Saturday, 17 October 2026European Markets

BELUGA Stock Over 16% Down In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of BELUGA (BEL 20: BELU.BR) fell by a staggering 16.67% in 5 sessions from €3 to €2.50 at 05:11 EST on Tuesday, after five successive sessions in a row of losses. BEL 20 is rising 0.12% to €3,507.13, after two successive sessions in a row of gains.

About BELUGA

Beluga NV is a private equity and venture capital firm specializing in investments in mid venture, late venture, middle market, and mature companies. It also invests in growth capital, later stages, and buyouts. The firm invests across all sectors in companies based in Belgium with a focus on the Flanders region. It usually invests between €0.25 million ($0.37 million) and €2.5 million ($3.75 million) in the form of a minority stake in both public and private companies. The firm typically invests in companies with enterprise value between €1 million ($1.50 million) and €250 million ($375.7 million), sales values between €0.25 million ($0.37 million) and €500 million ($751.41 million), and EBITDA values between €1 million ($1.50 million) and €100 million ($150.28 million). The firm sources its capital through the stock market. Beluga NV was founded in 1998 and is based in Ternat, Belgium.

Earnings Per Share

As for profitability, BELUGA has a trailing twelve months EPS of €0.02.

PE Ratio

BELUGA has a trailing twelve months price to earnings ratio of 125. Meaning, the purchaser of the share is investing €125 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BELUGA's stock is considered to be overbought (>=80).

More news about BELUGA (BELU.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com